» Articles » PMID: 37428074

The Lactate/H Transporter PfFNT Is Essential and Druggable

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Malaria parasites in the blood stage express a single transmembrane transport protein for the release of the glycolytic end product l-lactate/H from the cell. This transporter is a member of the strictly microbial formate-nitrite transporter (FNT) family and a novel putative drug target. Small, drug-like FNT inhibitors potently block lactate transport and kill Plasmodium falciparum parasites in culture. The protein structure of Plasmodium falciparum FNT (PfFNT) in complex with the inhibitor has been resolved and confirms its previously predicted binding site and its mode of action as a substrate analog. Here, we investigated the mutational plasticity and essentiality of the PfFNT target on a genetic level, and established its druggability using mouse malaria models. We found that, besides a previously identified PfFNT G107S resistance mutation, selection of parasites at 3 × IC (50% inhibitory concentration) gave rise to two new point mutations affecting inhibitor binding: G21E and V196L. Conditional knockout and mutation of the PfFNT gene showed essentiality in the blood stage, whereas no phenotypic defects in sexual development were observed. PfFNT inhibitors mainly targeted the trophozoite stage and exhibited high potency in P. berghei- and P. falciparum-infected mice. Their activity profiles were comparable to that of artesunate, demonstrating strong potential for the further development of PfFNT inhibitors as novel antimalarials.

Citing Articles

Addressing the Intracellular Vestibule of the Plasmodial Lactate Transporter PfFNT by p-Substituted Inhibitors Amplifies In Vitro Activity.

Nerlich C, Tiedjens F, Hertel R, Henke B, Hauer S, Panitzsch L J Med Chem. 2024; 67(20):18368-18383.

PMID: 39361938 PMC: 11513924. DOI: 10.1021/acs.jmedchem.4c01674.


Microbial membrane transport proteins and their biotechnological applications.

Ozkan M, Yilmaz H, Ergenekon P, Erdogan E, Erbakan M World J Microbiol Biotechnol. 2024; 40(2):71.

PMID: 38225445 PMC: 10789880. DOI: 10.1007/s11274-024-03891-6.


Critical interdependencies between Plasmodium nutrient flux and drugs.

Henshall I, Spielmann T Trends Parasitol. 2023; 39(11):936-944.

PMID: 37716852 PMC: 10580322. DOI: 10.1016/j.pt.2023.08.008.

References
1.
Marchetti R, Lehane A, Shafik S, Winterberg M, Martin R, Kirk K . A lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparum. Nat Commun. 2015; 6:6721. DOI: 10.1038/ncomms7721. View

2.
Sherman W, Beard H, Farid R . Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006; 67(1):83-4. DOI: 10.1111/j.1747-0285.2005.00327.x. View

3.
Fidock D, Rosenthal P, Croft S, Brun R, Nwaka S . Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004; 3(6):509-20. DOI: 10.1038/nrd1416. View

4.
Charman S, Arbe-Barnes S, Bathurst I, Brun R, Campbell M, Charman W . Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A. 2011; 108(11):4400-5. PMC: 3060245. DOI: 10.1073/pnas.1015762108. View

5.
Golldack A, Henke B, Bergmann B, Wiechert M, Erler H, Blancke Soares A . Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. PLoS Pathog. 2017; 13(2):e1006172. PMC: 5298233. DOI: 10.1371/journal.ppat.1006172. View